DOSSIER · 13F-HR · Q2 2026

Fairmount Funds Management LLC

$1.5B in tracked AUM across 12 positions as of Q2 2026.

FF
CIK 0001802528 · last filed Jun 30, 2026
Total AUM
$1.5B
as of Q2 2026
Holdings
12
positions
Whale Score
79
79
strong
Activity
no data
changes this Q
AI Analysis · Q2 2026

Fairmount Funds Management's $1.38B 13F shows a manager in balanced rebalancing mode: two positions increased, two decreased, three sold out, two new entries, and six unchanged. That symmetric activity profile — neither net accumulation nor net liquidation — reads as a manager actively managing toward target weights within its existing research perimeter. The portfolio edged down slightly from $1.31B, implying modest net selling or performance headwind in a concentrated book. The WhaleScore of 79 reflects a long-term record from this concentrated approach, and this quarter's filing is consistent with a mature mandate that makes regular rebalancing decisions rather than dramatic directional rotations.

The three sold-out positions are the most analytically interesting feature. In a concentrated book, a full liquidation is a deliberate decision that the capital can be better deployed elsewhere. The fact that three positions were exited while only two new ones entered suggests the manager is narrowing rather than expanding its idea set.

The two increased positions represent the manager's highest-conviction names — the ones that survived the rebalancing and received fresh capital. The two new entries represent fresh research deployment into names the manager believes have moved into its buy-parameter range.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
ORKA
ORUKA THERAPEUTICS INC
$353M3.7M23.3%
02
DNTH
DIANTHUS THERAPEUTICS INC
$247M2.5M16.3%
03
GLTO
DAMORA THERAPEUTICS INC
$227M8.7M15.0%
04
COGT
COGENT BIOSCIENCES INC
$213M5.5M14.1%
05
JBIO
JADE BIOSCIENCES INC
$101M4.6M6.7%
06
ELVN
ENLIVEN THERAPEUTICS INC
$94M1.9M6.2%
07
VRDN
VIRIDIAN THERAPEUTICS INC
$94M5.1M6.2%
08
ZBIO
ZENAS BIOPHARMA INC
$60M2.4M4.0%
09
G2545C104
CRESCENT BIOPHARMA INC.
$49M2.7M3.3%
10
APGE
APOGEE THERAPEUTICS INC
$40M299K2.6%

Filing history

2026Q2Jun 30
$1.5B 9.3%
12 positionsView →
2026Q1Mar 31
$1.4B 5.4%
12 positionsView →
2025Q4Dec 31
$1.3B 76.7%
13 positionsView →
2025Q3Sep 30
$743M 3.7%
12 positionsView →
2025Q2Jun 30
$772M 19.7%
17 positionsLocked
2025Q1Mar 31
$645M 35.9%
15 positionsLocked
2024Q4Dec 31
$1.0B 18.4%
17 positionsLocked
2024Q3Sep 30
$1.2B 39.3%
15 positionsLocked
2024Q2Jun 30
$885M 3.5%
13 positionsLocked
2024Q1Mar 31
$917M 3.1%
15 positionsLocked
2023Q4Dec 31
$946M 13.9%
16 positionsLocked
2023Q3Sep 30
$831M 17.2%
20 positionsLocked
Showing 12 of 27